Tissue plasminogen activator, tissue plasminogen activator inhibitor and lipoprotein(a) in patients with coronary, eplaortic and peripheral occlusive artery disease

Abstract

In order to evaluate the relationship between the presence of atherosclerotic disease, documented by angiography, and the fibrinolytic profile, 262 consecutive patients affected by coronary (n = 90), epiaortic (n = 60) and peripheral (n = 104) artery disease have been included in the study. Twenty-two healthy subjects were used as controls for laboratory parameters determination. All patients were classified on the basis of the presence (S+) or absence (S-) of clinically significant stenosis, according to specific scoring systems. Lipoprotein(a), plasminogen activator inhibitor (PAI-1), tissue plasminogen activator (t-PA) and the PAI-1/t-PA ratio were significantly lower in controls than in coronary, epiaortic and peripheral artery disease patients. However, the levels of these parameters were not statistically different between S+ and S- subjects. These results confirm the association between lipoprotein(a), PAI-1 and t-PA levels and the presence of atherosclerotic disease independently of the arterial districts considered, while they do not appear to be directly linked to the severity of the morphological disease.

Endothelial Function, Variables of Fibrinolysis and Coagulation in Smokers and Healthy Controls

“…Associations between an impaired TPA/PAI ratio as well as alterations in PAP and endpoints of cardiovascular diseases are described [14,15]. There is also evidence indicating an association between fibrinolytic variables and a substantially increased IMT, especially in elderly subjects [20].…”

“…unstable angina pectoris or myocardial infarction [11][12][13], and that some markers have a prognostic significance for future myocardial events [14]. Changes seem to be independent of the location of the atherosclerotic lesions [15]. Conflicting results exist concerning the associations between chronic smoking and alterations in hemostasis [16][17][18][19][20], since these associations might well be influenced by other cardiovascular risk factors [16].…”

The Activation of Plasminogen Activator Inhibitor-1 Expression by IL-1β Is Attenuated by Estrogen in Hepatoblastoma HepG2 Cells Expressing Estrogen Receptor α

“…Since inflammation plays a major role in the development of atherosclerosis, it is conceivable that the induction of cytokines by atherogenic factors leads to an elevation in PAI-1 (11). Cardiovascular disease manifestations and risk factors associated with elevated PAI-1 levels include vascular stenosis, menopause, insulin resistance and dyslipidemia (6,7,(12)(13)(14)(15).…”